Dirithromycin metabolite

Details Dirithromycin metabolite Dirithromycin metabolite

1987-05-26

1990-07-31

Brown, Johnnie R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 72, 536 74, A61K 3170, C07H 1708

Patent

active

049450808

ABSTRACT:
Novel macrolide, AS-E 136 metabolite, is obtained from the body fluids of animals receiving AS-E 136 or erythromycylamine. Methods for treating infections caused by pathogenic bacteria, especially Gram-positive bacteria, and pharmaceutical compositions containing the metabolite are provided.

REFERENCES:
patent: 3772270 (1973-11-01), Gerzon et al.
patent: 4048306 (1987-09-01), Maier et al.
patent: 4755385 (1988-07-01), Etienne et al.
T. Lazarevski et al., "Erythromycin Series v. Quantitative Analysis of Cladinose and Methylcladinoside by Densitometry of Thin-Layer Chromatograms", J. Chromatography 132, 309-313 (1977).
M. Chen and W. L. Chiou, "Analysis of Erythromycin in Biological Fluids by High-Performance Liquid Chromatography with Electrochemical Detection", J. Chromatography 278, 91-100 (1983).

Affiliated with

Also associated with

Rating

Dirithromycin metabolite does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dirithromycin metabolite, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dirithromycin metabolite will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1398803